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Abstract 
Medium chain acyl CoA dehydrogenase deficiency (MCAD) is the most common inborn 
error of fatty acid oxidation. This condition may lead to cellular energy shortage and cause 
severe clinical events such as hypoketotic hypoglycemia, Reye syndrome and sudden death. 
MCAD deficiency usually presents around three to six months of life, following catabolic 
stress as intercurrent infections or prolonged fasting, whilst neonatal-onset of the disease is 
quite rare. We report the case of an apparently healthy newborn who suddenly died at the 
third day of life, in which the diagnosis of MCAD deficiency was possible through peri-
mortem blood-spot acylcarnitine analysis that showed very high concentrations of 
octanoylcarnitine. Genetic analysis at the ACADM locus confirmed the biochemical findings 
by demonstrating the presence in homozygosity of the frame-shift c.244dup1 
(p.Trp82LeufsX23) mutation, a severe genotype that may explain the unusual and very early 
fatal outcome in this newborn. This report confirms that inborn errors of fatty acid oxidation 
represent one of the genetic causes of sudden unexpected deaths in infancy (SUDI) and 
underlines the importance to include systematically specific metabolic screening in any 
neonatal unexpected death. 
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Background 
Specific genetic conditions may lead to sudden unexpected deaths in infancy (SUDI), such as 
inborn errors of fatty acid oxidation and genetic disorders of cardiac ion channels [1]. 
Medium chain acyl CoA dehydrogenase (MCAD) deficiency (OMIM 201450) is an 
autosomal recessive disorder and represents the most common fatty acid oxidation disorder 
with an incidence around 1:8,000 [2]. The disease may present dramatically with severe 
hypoketotic hypoglycemia, Reye syndrome or sudden death, typically with a peak of 
frequency around 3–6 month, whilst neonatal SUDI is quite rare. When undetected, 
approximately 20–25% of infants will die or suffer permanent neurologic impairment as a 
consequence of the first acute metabolic decompensation. Detection of MCAD deficiency 
through newborn screening, however, has allowed counseling of parents and primary care to 
prevent fasting stress in pre-symptomatic infants [3]. Here we report the case of a newborn 
affected by MCAD deficiency and homozygous for a severe genetic mutation who suddenly 
died at the third day of life. 
Case Presentation 
The child was born by spontaneous delivery at 40th week of gestation after normal pregnancy 
from healthy consanguineous parents. APGAR score was 8/9 and anthropometric parameters 
were within the normal percentiles. 
On third day of life, when discharge was already scheduled, the baby had sudden cardiac-
respiratory arrest and immediate resuscitation was performed. Despite prompt resuscitation 
the patient died in the following hours because of irreversible multi-organ failure. 
First laboratory investigation revealed profound hypoglycaemia (0.5 mmol/l) and mild 
hyperammonemia (176 μmol/l). Blood spot and urine collection allowed specific metabolic 
investigation that showed very marked elevation of medium chain acylcarnitines as hexanoyl 
carnitine (C6), (blood spot concentration at 1.75 μmol/L; normal value <0.20), octanoyl 
carnitine (C8), (blood spot concentration at 36.74 μmol/L; normal value < 0.23), decenoyl 
carnitine (C10), (blood spot concentration at 1.74 μmol/L; normal value <0.22), in 
association with high urinary excretion of suberylglycine (7.7 μMol/mMol Creatinine; normal 
value <2) and exanoylglycine (4.8 μMol/mMol Creatinine; normal value <2). These 
metabolic findings were formally consistent with the diagnosis of MCAD deficiency. In order 
to confirm the diagnosis at molecular level, the genomic DNA was isolated from a whole 
sample blood collected and informed consent for genetic testing obtained from parents. 
Mutation analysis of ACADM gene revealed homozygosity for the c.244dup1 
(p.Trp82LeufsX23) single base duplication. This mutation leads to a severe frame-shift with 
the introduction of a premature stop codon. Both parents were heterozygous for such 
mutation at molecular analysis. 
Discussion 
Sudden infant death syndrome (SIDS) is a multifactorial disorder influenced by 
developmental, environmental, and biological risk factors and it is defined as the sudden 
death of an infant that is unexpected by history and unexplained by postmortem 
examinations. SIDS is a leading cause of infant mortality, accounting for 8% of all infant 
deaths [4] and it is the most common cause of post neonatal infant mortality accounting for 
40-50% of all deaths between one month and one year of age. Cases in which instead the 
cause is identified should be diagnosed not as SIDS but as SUDI, such as in specific genetic 
conditions. At present, long QT syndrome and fatty acid β-oxidation disorders represent the 
most frequent inherited causes of SUDI [1]. 
Long QT syndrome is caused by mutations in genes encoding cardiac ion channels (such as 
KVLQT1, HERG, KCNE1, and KCNE2) leading to prolonged cardiac action potential by 
either increasing depolarization or decreasing repolarization current and so causing syncope, 
seizures or sudden death [1]. 
Fatty acid β-oxidation disorders encompass almost 20 different inborn enzymopathies. 
Among them, medium chain acyl CoA dehydrogenase (MCAD) deficiency is largely the 
most frequent condition with incidence around 1: 8,000 [2]. The enzymatic defect results in a 
blockade of medium chain fatty acids breakdown and of ketone production. The enzymatic 
deficiency compromises the availability of ketones during prolonged fasting or acute illness. 
This energy shortage primarily affects function of skeletal and cardiac muscle as well as the 
brain, and can lead to death. MCAD deficiency is usually silent and generally affects 
individuals clinically normal until an intercurrent illness episode triggers hypoglycemia and 
fatty acids discharge [5]. 
The most common clinical presentations of the disease include hypoketotic hypoglycemia, 
Reye syndrome and, more dramatically, sudden unexpected death, generally during the first 
year of life. Surviving patients who comply with a treatment regimen, which essentially relies 
on avoidance of fasting, either dramatically reduce or completely eliminate recurrent life-
threatening disease episodes [6]. The biochemical diagnosis is based on acylcarnitine profile, 
characterized by accumulation of hexanoyl-carnitine (C6) to decanoyl-carnitine (C10) 
species, with prominent octanoyl-carnitine (C8). Patients also show a characteristic urinary 
organic acids pattern, with typical dicarbossilic aciduria and elevated hexanoyl and 
suberylglycine. The diagnosis can be confirmed by molecular analysis of ACADM gene 
(1p31.1) which encodes for MCAD protein [7]. To date more then 90 mutations have been 
reported in the ACADM gene (HGMD - Human Genome Mutation Database) [8]. 
The c.985A>G missense mutation is the most frequent molecular lesion and may account up 
to 90% of alleles of clinically diagnosed MCAD deficient patients, but is lower in cases 
ascertained by screening [9]. This suggests that this mutation may be more likely to lead to a 
severe clinical phenotype [9,10]. Although there is no “safe” genotype or metabolite profile 
for MCAD deficiency, profoundly elevated C8 on blood spot or the presence of severe 
mutations may reflect impaired ability to tolerate metabolic stress potentially leading to more 
severe or lethal phenotypes as confirmed in the MCAD deficient patient here reported who 
presented with neonatal SUDI. 
Sudden neonatal death represents an unusual clinical presentation of MCAD deficiency, 
possibly related to specific severe genotypes, such as the homozygosity for the frame-shift 
c.244dup1(p.Trp82LeufsX23) mutation [11]. Unfortunately, neonatal death due to MCAD 
deficiency could be not prevented by routine newborn screening programs, as sampling for 
blood spot acylcarnitine analysis is generally carried out after 48 hours of life and results 
might not be available before the onset of acute clinical events. Nevertheless, expecially in 
those States in which expanded metabolic newborn screening is not yet available, to provide 
definite diagnosis and accurate genetic counseling in any sudden neonatal death, fatty acid 
oxidation inborn disorders must be routinely explored by collecting simple biological 
material as blood spot, that may be easily sent to specialized laboratories for acylcarnitine 
and/or DNA analysis. 
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